Welcome to our dedicated page for TG THERAPEUTICS SEC filings (Ticker: TGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TG Therapeutics' SEC filings document a commercial-stage biotechnology issuer whose common stock trades on the Nasdaq Capital Market under TGTX. The filings cover operating results and financial condition, BRIUMVI product revenue and revenue guidance, license, royalty and other commercialization revenue, and research and development spending tied to its B-cell disease pipeline.
Material-event filings also record capital-structure actions such as senior secured credit financing, repayment of prior term loans, and related borrowing terms. Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting matters, and governance practices for the public company.
Lonial Sagar reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Sagar Lonial received a grant of 8,325 stock tracking units. Each unit is a contingent right to either one share of common stock or a cash payment equal to the fair market value of one share, generally within 30 days after the first anniversary of grant. The units vest on that first anniversary if he remains in continuous service, and this filing shows 8,325 units held after the grant.
HUME DANIEL reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Daniel Hume reported a compensation grant of 8,325 Stock Tracking Units (STUs). Each STU is a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share, no later than 30 days after the first anniversary of the grant date. The STUs vest on the first anniversary only if he remains in continuous service with the company, and he now holds 8,325 STUs directly.
Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Kenneth Hoberman received an equity-based award tied to the company’s stock. He was granted 8,325 Stock Tracking Units on June 11, 2026, each linked to one share of common stock.
Each unit represents a contingent right, at the board committee’s discretion, to deliver either one share of common stock or a cash payment equal to the fair market value of one share, no later than 30 days after the first anniversary of the grant date. The units will vest on the first anniversary of the grant, provided he remains in continuous service with the company through that date.
Echelard Yann reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Yann Echelard received a grant of 8,325 stock tracking units as equity compensation. Each unit represents a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share. The committee administering the company’s 2022 Incentive Plan will choose stock or cash, and settlement must occur within 30 days after the first anniversary of the grant date. The units vest on the first anniversary of grant if Echelard remains in continuous service with the company.
TG Therapeutics director Laurence N. Charney received a grant of 8,325 Stock Tracking Units on June 11, 2026. These units were awarded as compensation and carry no exercise price.
Each Stock Tracking Unit represents a contingent right, at the discretion of the plan committee, to receive either one share of TG Therapeutics common stock or a cash payment equal to the fair market value of one share. This payment or share delivery is scheduled no later than 30 days after the first anniversary of the grant date, provided Charney remains in continuous service through that vesting date.
Following this award, Charney holds 8,325 Stock Tracking Units directly, each tied to an equivalent number of underlying common shares. The transaction does not involve any open-market buying or selling, and reflects a routine equity-based incentive grant.
TG Therapeutics, Inc. reported results from its 2026 Annual Meeting, where stockholders representing 113,003,414 shares, or 73.81% of the 153,093,879 outstanding shares, were present, constituting a quorum. Six directors were elected, KPMG LLP was ratified as independent auditor, but the advisory vote on executive compensation was not approved, with 31,905,837 votes for and 48,858,169 against.
TG Therapeutics reported positive Phase 1 results for a high‑concentration, low‑volume subcutaneous formulation of BRIUMVI (ublituximab-xiiy) in adults with relapsing multiple sclerosis. The subcutaneous version was well tolerated and showed sustained drug exposure, supporting a quarterly dosing regimen.
These data underpin an ongoing, fully enrolled Phase 3 trial comparing quarterly and every‑other‑month subcutaneous dosing to the approved intravenous regimen, with topline results expected in late 2026 or early 2027. Management noted that, if ultimately approved, a self‑administered at‑home, quarterly anti‑CD20 therapy could significantly reduce injections versus current options and expand the addressable BRIUMVI market.
TG Therapeutics reported positive topline results from its Phase 3 ENHANCE trial of BRIUMVI in adults with relapsing forms of multiple sclerosis. The study met its primary endpoint, showing bioequivalent drug exposure between the currently approved two-step initiation regimen and a single 600 mg infusion on Day 1.
This consolidated regimen would eliminate the Day 15 infusion while keeping the same total 600 mg dose through Day 15. Safety and tolerability of the single-infusion start were consistent with the established BRIUMVI safety profile. The company is targeting submission of a supplemental biologics license application in the second half of 2026.
TG Therapeutics reported strong growth and continued profitability for the quarter ended March 31, 2026. Total revenue reached $204.9 million, up from $120.9 million a year earlier, driven mainly by BRIUMVI sales of $201.3 million, including $194.8 million in the U.S. and $6.5 million to ex-U.S. partner Neuraxpharm.
Net income rose to $19.8 million from $5.1 million, with diluted earnings per share of $0.12. The company ended the quarter with $572.8 million in cash, cash equivalents and investment securities and estimates these resources, together with projected revenues, will fund operations for more than twelve months.
TG Therapeutics refinanced its prior $250 million term loan with a new $750 million term loan maturing in 2031, recognizing a $9.2 million loss on extinguishment of debt. It also continued its share repurchase activity, holding 6.9 million shares in treasury at a cost of about $200.2 million.
TG Therapeutics reported sharply improved first quarter 2026 results, driven by strong uptake of BRIUMVI for multiple sclerosis. Total revenue reached $204.9 million, up from $120.9 million a year earlier, producing operating income of $34.8 million and net income of $19.8 million.
Product revenue, mainly from BRIUMVI, was $201.3 million, while cash, cash equivalents and investment securities grew to $572.8 million as of March 31, 2026. Despite higher research, selling, general and administrative expenses, profitability and cash balances increased.
Reflecting this momentum, the company raised its full-year 2026 total global revenue target to about $925 million and increased its BRIUMVI U.S. net product revenue guidance to $885–900 million, signaling confidence in ongoing demand and commercial execution.